Inhibrx Biosciences, Inc.
INBX- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0002007919
In the last 90 days, Inhibrx Biosciences, Inc. insiders filed 6 open-market purchases and 2 sales; 162 institutions reported holding it in 13F filings for Q2 2026, worth $1.36B in total; Viking Global Investors is the only superinvestor holding it.
Superinvestors holding INBX, Q2 2026
1 superinvestor reports holding Inhibrx Biosciences, Inc. on Form 13F, worth $106.5M in total. Weight is Inhibrx Biosciences, Inc.'s share of each 13F portfolio; actions compare shares with Q1 2026.
| Superinvestor | % of portfolio | Shares | Value | vs. previous quarter |
|---|---|---|---|---|
| Viking Global InvestorsAndreas Halvorsen | 0.3% | 1,123,929 | $106.5M | Reduced−21.8% |
Moves by quarter
Superinvestors that opened, added to, trimmed or sold out of INBX each quarter, comparing shares with the quarter before. A superinvestor that didn't file for a quarter isn't listed, and isn't counted as selling.
Q2 2026
1 superinvestor holding at quarter end
- Reduced
- Viking Global Investors (−21.8%)
Q4 2025
1 superinvestor holding at quarter end
- Reduced
- Viking Global Investors (−19.6%)
Q2 2024
1 superinvestor holding at quarter end
- Reduced
- Viking Global Investors (−75.0%)
Q3 2023
1 superinvestor holding at quarter end
- Added
- Viking Global Investors (+7.7%)
Q4 2022
1 superinvestor holding at quarter end
- Added
- Viking Global Investors (+25.1%)